$855M LG Chem License Deal Brings $450M Upfront Cash to Rhythm Pharma
RYTM sits 25% above its 52-week low of $74.5 on elevated volume (3.0× avg).
Summary
Rhythm Pharmaceuticals signed an $855 million license-out agreement with LG Chem, including a $450 million upfront payment and $405 million in milestones. The upfront alone is roughly six times Rhythm's Q2 2026 revenue of $71.3 million, a transformative cash infusion for a company with a $6.4 billion market cap. This is the first major partnership headline for Rhythm after a run of regulatory wins — UK, Japan, and Canada approvals for IMCIVREE in acquired hypothalamic obesity — and it validates the franchise with outside capital. The deal terms disclosed so far do not specify which asset or territory LG Chem is licensing, so the strategic scope remains unclear. Watch for the 8-K detailing the agreement structure and any milestone triggers.
At the time of this announcement, RYTM was trading at $93.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $74.50 to $122.20. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.